MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
372.96%
Quick Ratio
372.96%
Cash Ratio
159.50%
Debt to Asset Ratio
26.79%
Unit: Dollar
Assets Breakdown
    • Receivable from issuance of warr...
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Common stock, 0.001 par value 75...
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
2,388,135
2,308,137
4,007,789
3,860,082
Receivable from issuance of warrants
2,684,904
-
-
-
Interest receivable
5,305
5,466
5,096
12,791
Prepaid expenses and other current assets
410,105
428,071
200,140
116,015
Deferred offering costs
95,674
113,607
106,342
90,838
Total current assets
5,584,123
2,855,281
4,319,367
4,079,726
Property, plant and equipment, net
2,675
4,619
5,174
5,729
Other assets
2,167
2,167
2,167
2,167
Total assets
5,588,965
2,862,067
4,326,708
4,087,622
Accounts payable
871,913
824,809
650,663
614,127
Accrued liabilities
625,344
240,143
937,319
738,548
Total current liabilities
1,497,257
1,064,952
1,587,982
1,352,675
Total liabilities
1,497,257
1,064,952
1,587,982
1,352,675
Common stock, 0.001 par value 75,000,000 shares authorized, 3,098,592 shares issued and outstanding as of june 30, 2026 2,338,127 shares issued and outstanding as of december 31, 2025
3,098
2,507
2,338
2,059
Additional paid-in capital
48,867,860
43,251,293
41,696,533
38,654,043
Accumulated deficit
-44,779,250
-41,456,685
-38,960,145
-35,921,155
Total stockholders equity
4,091,708
1,797,115
2,738,726
2,734,947
Total liabilities and stockholders equity
5,588,965
2,862,067
4,326,708
4,087,622
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Receivable from issuance ofwarrants$2,684,904 Cash and cashequivalents$2,388,135 (-57.13%↓ Y/Y)Prepaid expenses andother current assets$410,105 (14.44%↑ Y/Y)Deferred offering costs$95,674 (300.96%↑ Y/Y)Interest receivable$5,305 (-72.14%↓ Y/Y)Total current assets$5,584,123 (-6.49%↓ Y/Y)Property, plant andequipment, net$2,675 (-37.46%↓ Y/Y)Other assets$2,167 (0.00%↑ Y/Y)Total assets$5,588,965 (-6.51%↓ Y/Y)Total liabilities andstockholders equity$5,588,965 (-6.51%↓ Y/Y)Total stockholdersequity$4,091,708 (-4.82%↓ Y/Y)Total liabilities$1,497,257 (-10.85%↓ Y/Y)Accumulated deficit-$44,779,250 (-34.73%↓ Y/Y)Additional paid-in capital$48,867,860 (30.20%↑ Y/Y)Total currentliabilities$1,497,257 (-10.85%↓ Y/Y)Common stock, 0.001 parvalue 75,000,000...$3,098 (54.44%↑ Y/Y)Accounts payable$871,913 (-2.65%↓ Y/Y)Accrued liabilities$625,344 (-20.23%↓ Y/Y)

Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics, Inc. (CVKD)